{
  "paper_id": "PMC8812340",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812340/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "1.",
      "caption": "Study flow diagram.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/f108c1dc84e6/nCD004004-FIG-01.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "2.",
      "caption": "Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/6e654d5de3a9/tCD004004-FIG-02.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "3.",
      "caption": "Risk of bias summary: review authors' judgements about each risk of bias item for each included study.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/fc5f9dad69c9/tCD004004-FIG-03.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "1.1. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 1: Loss of 3 or more lines best‐corrected visual acuity lost at 12 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0005",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/98fe7898d144/tCD004004-CMP-001.01.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "1.2. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 2: Three or more lines visual acuity lost at 24 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0006",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/c3a2dcd9504e/tCD004004-CMP-001.02.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "1.3. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 3: Change in BCVA at 12 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0007",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/a7202eece318/tCD004004-CMP-001.03.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "4.",
      "caption": "",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0004",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/cce437db5732/tCD004004-FIG-04.jpg"
    },
    "figure_8": {
      "figure_number": "Figure 8",
      "title": "1.5. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 5: Change in contrast sensitivity",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0009",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_8.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/2fe83d4ee0ff/tCD004004-CMP-001.05.jpg"
    },
    "figure_9": {
      "figure_number": "Figure 9",
      "title": "2.1. Analysis.",
      "caption": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 1: Three or more lines visual acuity lost at 12 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0011",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_9.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/5bb0c0443e69/tCD004004-CMP-002.01.jpg"
    },
    "figure_10": {
      "figure_number": "Figure 10",
      "title": "2.2. Analysis.",
      "caption": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 2: Three or more lines visual acuity lost at 24 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0012",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_10.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/53db0904456c/tCD004004-CMP-002.02.jpg"
    },
    "figure_11": {
      "figure_number": "Figure 11",
      "title": "2.4. Analysis.",
      "caption": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 4: Change in BCVA at 24 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0014",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_11.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/4da539395779/tCD004004-CMP-002.04.jpg"
    },
    "figure_12": {
      "figure_number": "Figure 12",
      "title": "1.4. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 4: Change in BCVA at 24 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0008",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_12.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/d45d65833590/tCD004004-CMP-001.04.jpg"
    },
    "figure_13": {
      "figure_number": "Figure 13",
      "title": "1.6. Analysis.",
      "caption": "Comparison 1: Radiation therapy versus control, Outcome 6: Contrast sensitivity raw data",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0010",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_13.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/76276da2c966/tCD004004-CMP-001.06.jpg"
    },
    "figure_14": {
      "figure_number": "Figure 14",
      "title": "2.3. Analysis.",
      "caption": "Comparison 2: Radiation therapy with anti‐VEGF versus anti‐VEGF alone, Outcome 3: Change in BCVA at 12 months",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "CD004004-fig-0013",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8812340/images/figure_14.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ce1/8812340/04be3c07d439/tCD004004-CMP-002.03.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Figure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 569, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Page 2241, figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 14,
    "claims_count": 72,
    "images_downloaded": 14,
    "tables_filtered": 2
  }
}